Cargando…
196. Antibodies to Vaccine-preventable Infections After CAR-T Cell Immunotherapy for B Cell Malignancies
BACKGROUND: Chimeric antigen receptor-modified T (CAR-T) cell immunotherapy for B cell hematologic malignancies results in prolonged B cell depletion. Little is known about the effects of CAR-T cell therapy on pre-existing pathogen-specific humoral immunity. METHODS: We conducted a prospective, cros...
Autores principales: | Walti, Carla S, Maalouf, Joyce, Boonyaratanakornkit, Jim, Keane-Candib, Jacob, Taylor, Justin J, Hirayama, Alexandre V, Bar, Merav, Gardner, Rebecca A, Green, Damian J, Boeckh, Michael, Maloney, David G, Krantz, Elizabeth M, Turtle, Cameron J, Hill, Joshua A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776444/ http://dx.doi.org/10.1093/ofid/ofaa439.506 |
Ejemplares similares
-
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
por: Walti, Carla S., et al.
Publicado: (2021) -
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy
por: Walti, Carla S., et al.
Publicado: (2021) -
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study
por: Walti, Carla S, et al.
Publicado: (2021) -
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022) -
Comparison of Humoral and T-Cell Response after Sars-Cov-2 Vaccination Among Patients before and after Chimeric Antigen Receptor-Modified T Cell (CAR-T cell) Therapy
por: Gonzalez, Michael A, et al.
Publicado: (2022)